CA2772907C - Selective antibacterials for clostridium difficile infections - Google Patents

Selective antibacterials for clostridium difficile infections Download PDF

Info

Publication number
CA2772907C
CA2772907C CA2772907A CA2772907A CA2772907C CA 2772907 C CA2772907 C CA 2772907C CA 2772907 A CA2772907 A CA 2772907A CA 2772907 A CA2772907 A CA 2772907A CA 2772907 C CA2772907 C CA 2772907C
Authority
CA
Canada
Prior art keywords
oxopurine
dichlorobenzylamino
morpholinyl
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2772907A
Other languages
English (en)
French (fr)
Other versions
CA2772907A1 (en
Inventor
George E. Wright
Wei-Chu Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLSynthesis Inc
Original Assignee
GLSynthesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLSynthesis Inc filed Critical GLSynthesis Inc
Publication of CA2772907A1 publication Critical patent/CA2772907A1/en
Application granted granted Critical
Publication of CA2772907C publication Critical patent/CA2772907C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2772907A 2009-09-11 2010-09-10 Selective antibacterials for clostridium difficile infections Active CA2772907C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27643609P 2009-09-11 2009-09-11
US61/276,436 2009-09-11
PCT/US2010/048379 WO2011031935A1 (en) 2009-09-11 2010-09-10 Selective antibacterials for clostridium difficile infections

Publications (2)

Publication Number Publication Date
CA2772907A1 CA2772907A1 (en) 2011-03-17
CA2772907C true CA2772907C (en) 2018-01-09

Family

ID=43732808

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2772907A Active CA2772907C (en) 2009-09-11 2010-09-10 Selective antibacterials for clostridium difficile infections

Country Status (5)

Country Link
US (1) US8796292B2 (https=)
EP (1) EP2475252B1 (https=)
JP (1) JP5934647B2 (https=)
CA (1) CA2772907C (https=)
WO (1) WO2011031935A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
KR102941194B1 (ko) * 2018-12-21 2026-03-19 아크룩스 파마슈티컬스, 인크. Dna 폴리머라제 iiic 억제제 및 그의 용도
CA3223983A1 (en) * 2021-06-16 2022-12-22 Acurx Pharmaceuticals, Inc. Use of ibezapolstat to promote microbiome health
CN120202009A (zh) * 2022-10-17 2025-06-24 阿科利斯制药股份有限公司 用于改善健康的化合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516905A (en) 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
WO2001028561A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
WO2001029045A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
WO2001029010A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6777420B2 (en) 2001-06-15 2004-08-17 Microbiotix, Inc. Heterocyclic antibacterial compounds
WO2002102792A1 (en) 2001-06-15 2002-12-27 Microbiotix, Inc. Novel heterocyclic antibacterial compounds
EP1472254A4 (en) * 2002-02-08 2006-02-15 Glsynthesis Inc PURINE AND ISOSTERIC ANTIBACTERIAL COMPOUNDS
WO2003103699A1 (en) * 2002-06-06 2003-12-18 Vicuron Pharmaceuticals Inc. Use of ramoplanin to treat diseases associated with the use of antibiotics
WO2004094370A2 (en) * 2002-09-10 2004-11-04 Microbiotix, Inc. Antibacterial pyrazole carboxylic acid hydrazides
FR2906244B1 (fr) * 2006-09-22 2010-09-10 Centre Nat Rech Scient Nouvelle classe de composes derives de terpene a activite antibiotique, compositions les contenant et utilisations.

Also Published As

Publication number Publication date
EP2475252A1 (en) 2012-07-18
US8796292B2 (en) 2014-08-05
CA2772907A1 (en) 2011-03-17
EP2475252B1 (en) 2016-11-16
JP5934647B2 (ja) 2016-06-15
EP2475252A4 (en) 2013-07-10
JP2013504592A (ja) 2013-02-07
US20120232077A1 (en) 2012-09-13
WO2011031935A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
EP0839040B1 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
CN108358917B (zh) 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
US20240190872A1 (en) Fabi inhibitors for gram-negative pathogens
CA2772907C (en) Selective antibacterials for clostridium difficile infections
MX2014013759A (es) (r) -nifuratel, su uso para el tratamiento de infecciones y sintesis de (r) y (s) -nifuratel.
US20250051300A1 (en) Gram-negative specific antibiotics sparing effect on gut microbiome
US20060148730A1 (en) Method of treating tuberculosis
HUP0700061A2 (en) Pyridopyrimidine and pyrimidinopyrimidine derivatives, process for their preparation and pharmaceutical compositions therof as antibacterials having dhfr inhibitor activity
CN100361975C (zh) 5－羟基－3－羧酸酯吲哚类衍生物及其制备方法
US20220024925A1 (en) Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof
US11534427B2 (en) Applications of novel thiazole derivative in treating inflammatory bowel diseases
US20220313631A1 (en) Compounds and methods for the treatment of parasitic infections
CA2601202C (en) New hybrid oligomers, their preparation process and pharmaceutical compositions containing them
US12054466B2 (en) Compounds for the treatment of clostridium difficile infection
US6822098B2 (en) Ester or amide derivatives
CN107674014B (zh) 含有异吲哚啉片段的3，5-二硝基苯甲酰胺类化合物及其制备方法
CN101395143A (zh) 用于治疗疟疾或aids的氮杂杂环化合物
CN110759889B (zh) 2-芳酰胺基取代的噻吩酰亚胺酯类化合物及其制备方法和用途
CN104892600B (zh) 7‑（3‑氨甲基‑4‑取代苄氧亚胺基‑1‑吡咯烷基）萘啶酮羧酸类化合物
WO2024154719A1 (ja) 抗菌組成物及び医薬並びに抗菌方法
EP4602037A1 (en) Method for inhibiting clostridioides difficile spore germination
HUP0004621A2 (hu) Egy HIV proteáz inhibitor fokozott orális felszívódást és biológiai hozzáférhetőséget mutató szulfátsója
JPWO1996026204A1 (ja) フェニルアミジノチオフェン誘導体およびそれを含有する抗炎症剤
HK1005363B (en) Use of cgmp - phosphodiesterase inhibitors to treat impotence

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150902

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250109

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250109

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909